Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

iRhythm Technologies, Inc. - Common Stock (NQ:IRTC)

141.00 -0.04 (-0.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iRhythm Technologies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results
From iRhythm
Via GlobeNewswire
Earnings Scheduled For February 20, 2025
Via Benzinga
iRhythm (IRTC) To Report Earnings Tomorrow: Here Is What To Expect
Medical technology company iRhythm Technologies (NASDAQ:IRTC) will be announcing earnings results tomorrow afternoon. Here’s what investors should know. 
Via StockStory
iRhythm Technologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From iRhythm
Via GlobeNewswire
Critical Insights From iRhythm Technologies Analyst Ratings: What You Need To Know
Via Benzinga
Forecasting The Future: 6 Analyst Projections For iRhythm Technologies
Via Benzinga
Earnings Preview For iRhythm Technologies
Via Benzinga
Beyond The Numbers: 9 Analysts Discuss iRhythm Technologies Stock
Via Benzinga
iRhythm Technologies Shares Preliminary Fourth Quarter 2024 Highlights and Business Update at the 43rd Annual J.P. Morgan Healthcare Conference
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From iRhythm
Via GlobeNewswire
Top 3 Robotics and Automation Stocks for the Next AI Boom
The next wave of AI will include interactive and autonomous AI and these three companies are making inroads into these areas today 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference
From iRhythm
Via GlobeNewswire
iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring
Five new studies span three focus areas for LTCM devices: digital engagement and patient satisfaction, arrhythmia patterns during sleep and activity, and the potential health care resource and economic... 
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Participate in the Wolfe Research 2024 Healthcare Conference
From iRhythm
Via GlobeNewswire
IRHYTHM ALERT: Bragar Eagel & Squire, P.C. is Investigating iRhythm Technologies, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device
From iRhythm
Via GlobeNewswire
iRhythm Technologies Announces Third Quarter 2024 Financial Results
From iRhythm
Via GlobeNewswire
Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy
From iRhythm
Via GlobeNewswire
Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio? 
Via Benzinga
Topics Government
Exposures Political
IRHYTHM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc. - IRTC
From Kahn Swick & Foti, LLC
Via Business Wire
Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results
Via Benzinga
With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says
FDA approves iRhythm's 510(k) submission for Zio AT device. A second approval may come soon, enhancing the company's mobile cardiac telemetry services. 
Via Benzinga
Exposures Product Safety
Crude Oil Rises Sharply; 3M Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Quest Diagnostics Posts Upbeat Results, Joins GM, Philip Morris And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device
Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients 
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024
From iRhythm
Via GlobeNewswire
IRHYTHM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc. - IRTC
From Kahn Swick & Foti, LLC
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.